FATE THERAPEUTICS GRANTED EXCLUSIVE LICENSE FOR STEM CELL MODULATORS
BY CHILDREN’S HOSPITAL BOSTON AND MASSACHUSSETTS GENERAL HOSPITAL
La Jolla, CA – May 15, 2009 – Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual
property rights jointly owned by Children’s Hospital Boston and Massachusetts General Hospital. This intellectual
property covers compositions and methods for supporting hematopoietic stem cells. These proprietary
technologies developed by Leonard Zon, M.D., director of the Stem Cell Program at Children’s Hospital Boston and
a scientific founder of Fate Therapeutics, expand the Company’s broad intellectual property portfolio for
modulating the activity and state of stem cells. Fate Therapeutics is utilizing its adult stem cell biology engine and
induced pluripotent stem (iPS) cell technology platform to develop Stem Cell Modulators (SCMs) – small molecules
and biologics that guide cell fate for therapeutic purposes.
"Over the past two years, Fate Therapeutics has amassed extensive intellectual property assets as a foundation for
our adult stem cell biology engine," said Paul Grayson, president and CEO of Fate Therapeutics. "The agreement
we signed today with Children’s Hospital and the technologies associated with it continue to expand our engine
and accelerate the Company’s core mission to develop small molecules and biologics that modulate adult stem
cells for regenerative medicine.”
The exclusive rights acquired today will be incorporated into Fate Therapeutics’ growing adult stem cell biology
engine, which also includes exclusive rights to the pioneering work of the Company’s scientific founders and other
leaders in the field. Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body
and are primarily responsible for maintaining and repairing their native tissue. An adult stem cell has unique
properties, in that it can renew itself and differentiate to become some or all of the major speciali